DrugId:  1
1. Name:  SB-249553
2. Groups:  Investigational
3. Description:  SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.
4. Indication:  lung cancer/melanoma 
DrugId:  2
1. Name:  Ecromeximab
2. Groups:  Investigational
3. Description:  Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
4. Indication:  Not Available
DrugId:  3
1. Name:  MDX-1379
2. Groups:  Investigational
3. Description:  MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma. 
4. Indication:  Investigated for use/treatment in melanoma.
DrugId:  4
1. Name:  IDD-3
2. Groups:  Investigational
3. Description:  IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines. It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells. 
4. Indication:  Investigated for use/treatment in melanoma.
DrugId:  5
1. Name:  Glembatumumab vedotin
2. Groups:  Investigational
3. Description:  A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
4. Indication:  Investigated for use/treatment in melanoma.
DrugId:  6
1. Name:  Rovalpituzumab Tesirine
2. Groups:  Investigational
3. Description:  Rovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
4. Indication:  Not Available
DrugId:  7
1. Name:  Volociximab
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
DrugId:  8
1. Name:  Intetumumab
2. Groups:  Investigational
3. Description:  Intetumumab has been used in trials studying the treatment of Melanoma.
4. Indication:  Not Available
DrugId:  9
1. Name:  Encorafenib
2. Groups:  Investigational
3. Description:  Encorafenib has been used in trials studying the treatment of Melanoma, Colorectal Cancer, Stage IV Melanoma, Recurrent Melanoma, and Metastatic Melanoma, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  Varlilumab
2. Groups:  Investigational
3. Description:  Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
4. Indication:  Not Available
DrugId:  11
1. Name:  AS1409
2. Groups:  Investigational
3. Description:  AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours. It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma.
4. Indication:  Investigated for use/treatment in kidney cancer and melanoma.
DrugId:  12
1. Name:  PRLX 93936
2. Groups:  Investigational
3. Description:  PRLX 93936 is selectively toxic to cancer cells.
4. Indication:  Investigated for use/treatment in solid tumors.
DrugId:  13
1. Name:  Denenicokin
2. Groups:  Investigational
3. Description:  Denenicokin is under investigation in clinical trial NCT01152788 (Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma).
4. Indication:  Not Available
DrugId:  14
1. Name:  VB2-011
2. Groups:  Investigational
3. Description:  VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).
4. Indication:  Investigated for use/treatment in cancer/tumors (unspecified).
DrugId:  15
1. Name:  Verubulin
2. Groups:  Investigational
3. Description:  Antineoplastic; a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
4. Indication:  Investigated for use/treatment in brain cancer, lung cancer, melanoma, and solid tumors.
DrugId:  16
1. Name:  Epacadostat
2. Groups:  Investigational
3. Description:  Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
4. Indication:  Not Available
DrugId:  17
1. Name:  Diethylnorspermine
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in renal cell carcinoma, pancreatic cancer, melanoma, and lung cancer.
DrugId:  18
1. Name:  NV-18
2. Groups:  Investigational
3. Description:  NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer of the gall bladder).
4. Indication:  Investigated for use/treatment in solid tumors.
DrugId:  19
1. Name:  Aviscumine
2. Groups:  Investigational
3. Description:  Cy 503 is under investigation in clinical trial NCT00658437 (Aviscumine for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy).
4. Indication:  Not Available
DrugId:  20
1. Name:  Talimogene laherparepvec
2. Groups:  Approved, Experimental, Investigational
3. Description:  Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities. It specifically replicates within tumor cells and causes lysis. It was approved by the FDA in 2015 under the market name Imlygic.
4. Indication:  Not Available
DrugId:  21
1. Name:  RAF-265
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in melanoma.
DrugId:  22
1. Name:  Diphencyprone
2. Groups:  Investigational
3. Description:  Diphencyprone has been used in trials studying the treatment and basic science of Melanoma, Ultraviolet Rays, Immunosuppression, Neoplasm Metastasis, and Hypersensitivity, Delayed, among others.
4. Indication:  Not Available
DrugId:  23
1. Name:  Tesetaxel
2. Groups:  Investigational
3. Description:  Tesetaxel has been used in trials studying the treatment of Cancer, Melanoma, Prostate Cancer, Gastric Carcinoma, and Advanced Melanoma, among others.
4. Indication:  Not Available
DrugId:  24
1. Name:  PI-88
2. Groups:  Investigational
3. Description:  PI-88 is a mixture of highly sulfated, monophosphorylated mannose oligosaccharides, derived from the extracellular phosphomannan of the yeast Pichia (Hansenula) holstii, with potential antiangiogenic activity.
4. Indication:  Investigated for use/treatment in hepatocellular carcinoma, liver cancer, melanoma, and multiple myeloma.
DrugId:  25
1. Name:  LM-609
2. Groups:  Investigational
3. Description:  LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors. In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis.
4. Indication:  Investigated for use/treatment in colorectal cancer, melanoma, prostate cancer, psoriasis and psoriatic disorders, rheumatoid arthritis, and solid tumors.
